X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Targeting Tumor-Positive Lymph Nodes Boosts Cancer Treatment

Content Team by Content Team
8th June 2023
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Scientists at Tohoku University in Japan have made a significant discovery in the field of cancer treatment. They have found a new approach to enhance the efficacy of immune checkpoint blockade (ICB), a type of cancer therapy that uses immune checkpoint inhibitors (ICIs), while also reducing the associated side effects. Their findings highlight the potential of utilizing ICIs to target tumor-positive lymph nodes, resulting in a potent anti-tumor response against both local and systemic metastases.

The immune system employs “checkpoint proteins” to regulate the activity of immune cells. However, cancer cells can exploit these checkpoints to evade detection by the immune system. ICB is an immunotherapy that aims to block these checkpoints, thereby empowering the immune system to combat cancer naturally, without directly attacking the cancer cells themselves. Nevertheless, the effectiveness of ICB can vary from person to person, and it can also lead to serious side effects known as immune-related adverse events (irAEs).

To improve the anti-tumor response while minimizing irAEs, the researchers hypothesized that targeting tumor-positive lymph nodes with ICB could be a promising approach. To test this hypothesis, they conducted experiments using anti-CTLA4, a commonly used ICI, on laboratory mice with lymph nodes and distant metastases. The results confirmed that directly administering CTLA4 blockers to tumor-positive lymph nodes resulted in a strong anti-tumor response against local and systemic metastases, leading to increased survival rates in the mice.

The anti-cancer effect observed was attributed to an increase in the functional T cell population within the tumor-positive lymph nodes and spleen. Non-specific CTLA4 blockades showed a diminished anti-tumor effect and worsened side effects, including interstitial pneumonia, associated with immune checkpoint inhibitors.

These findings carry substantial significance as they offer a simple and effective means to enhance the efficacy of ICB while minimizing its associated side effects. By targeting tumor-positive lymph nodes with ICIs, the anti-tumor response can be amplified, and the occurrence of irAEs can be reduced, leading to improved outcomes for cancer patients. Moving forward, Tohoku University plans to conduct further investigations and clinical trials to validate the efficacy of lymphatic targeted approaches in humans.

Previous Post

AMR Certification For Responsible Antibiotic Manufacturing

Next Post

Researchers Utilize AI To Combat Drug-Resistant Bacterium

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Researchers Utilize AI To Combat Drug-Resistant Bacterium

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In